(Q58614990)

English

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

scientific article published on 01 April 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

cancer research

0 references

phase III clinical trial

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Josep Tabernero Caturla

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

author name string

M C Alonso

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

B Ojeda

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M Llanos

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

C Solà

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M A Climent

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

M A Seguí

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

J J López

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

language of work or name

0 references

publication date

1 April 1995

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

15-24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

randomized experiment

0 references

https://scigraph.springernature.com/pub.10.1007/bf00666487

0 references

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Randomized trial comparing mitoxantrone with adriamycin in advanced breast cancer]

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of mitoxantrone and doxorubicin in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitomycin C and vinblastine chemotherapy for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA

1 reference

https://pubmed.ncbi.nlm.nih.gov/7749156

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00666487

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7749156%20AND%20SRC:MED&resulttype=core&format=json

25 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58614990&oldid=1983035951"